BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 35383292)

  • 1. The genotypes and phenotypes of missense mutations in the proline domain of the p53 protein.
    Hoyos D; Greenbaum B; Levine AJ
    Cell Death Differ; 2022 May; 29(5):938-945. PubMed ID: 35383292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor-derived mutations within the DNA-binding domain of p53 that phenotypically resemble the deletion of the proline-rich domain.
    Roth J; Koch P; Contente A; Dobbelstein M
    Oncogene; 2000 Mar; 19(14):1834-42. PubMed ID: 10777217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unraveling the Structural Changes in the DNA-Binding Region of Tumor Protein p53 (
    Balasundaram A; Doss CGP
    Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72-polymorphic p53.
    Bergamaschi D; Samuels Y; Sullivan A; Zvelebil M; Breyssens H; Bisso A; Del Sal G; Syed N; Smith P; Gasco M; Crook T; Lu X
    Nat Genet; 2006 Oct; 38(10):1133-41. PubMed ID: 16964264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential levels of transcription of p53-regulated genes by the arginine/proline polymorphism: p53 with arginine at codon 72 favors apoptosis.
    Jeong BS; Hu W; Belyi V; Rabadan R; Levine AJ
    FASEB J; 2010 May; 24(5):1347-53. PubMed ID: 20019240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The adapter protein CD2AP binds to p53 protein in the cytoplasm and can discriminate its polymorphic variants P72R.
    Panni S; Salvioli S; Santonico E; Langone F; Storino F; Altilia S; Franceschi C; Cesareni G; Castagnoli L
    J Biochem; 2015 Feb; 157(2):101-11. PubMed ID: 25261582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p53 codon 72 proline/arginine polymorphism and autoimmune thyroid diseases.
    Chen RH; Chang CT; Wang TY; Huang WL; Tsai CH; Tsai FJ
    J Clin Lab Anal; 2008; 22(5):321-6. PubMed ID: 18803266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TP53 codon 72 polymorphism and P53 protein expression in colorectal cancer specimens in Isfahan.
    Dastjerdi MN
    Acta Med Iran; 2011; 49(2):71-7. PubMed ID: 21598212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of p53 protein core domain structural alteration on ovarian cancer survival.
    Rose SL; Robertson AD; Goodheart MJ; Smith BJ; DeYoung BR; Buller RE
    Clin Cancer Res; 2003 Sep; 9(11):4139-44. PubMed ID: 14519637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation between human papillomavirus-associated cervical cancer and p53 codon 72 arginine/proline polymorphism.
    Tachezy R; Mikysková I; Saláková M; Van Ranst M
    Hum Genet; 1999 Dec; 105(6):564-6. PubMed ID: 10647890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The p53 codon 72 proline allele is associated with p53 gene mutations in non-small cell lung cancer.
    Hu Y; McDermott MP; Ahrendt SA
    Clin Cancer Res; 2005 Apr; 11(7):2502-9. PubMed ID: 15814626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mouse mutants reveal that putative protein interaction sites in the p53 proline-rich domain are dispensable for tumor suppression.
    Toledo F; Lee CJ; Krummel KA; Rodewald LW; Liu CW; Wahl GM
    Mol Cell Biol; 2007 Feb; 27(4):1425-32. PubMed ID: 17158931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TP53 mutations and Arg72Pro polymorphism in breast cancers.
    Denisov EV; Cherdyntseva NV; Litvyakov NV; Slonimskaya EM; Malinovskaya EA; Voevoda MI; Belyavskaya VA; Stegniy VN
    Cancer Genet Cytogenet; 2009 Jul; 192(2):93-5. PubMed ID: 19596263
    [No Abstract]   [Full Text] [Related]  

  • 14. Integrating mutation data and structural analysis of the TP53 tumor-suppressor protein.
    Martin AC; Facchiano AM; Cuff AL; Hernandez-Boussard T; Olivier M; Hainaut P; Thornton JM
    Hum Mutat; 2002 Feb; 19(2):149-64. PubMed ID: 11793474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the combined effect of p53 codon 72 polymorphism and hotspot mutations in response to anticancer drugs.
    Vikhanskaya F; Siddique MM; Kei Lee M; Broggini M; Sabapathy K
    Clin Cancer Res; 2005 Jun; 11(12):4348-56. PubMed ID: 15958617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential regulation of cellular target genes by p53 devoid of the PXXP motifs with impaired apoptotic activity.
    Zhu J; Jiang J; Zhou W; Zhu K; Chen X
    Oncogene; 1999 Mar; 18(12):2149-55. PubMed ID: 10321740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The requirement for the p53 proline-rich functional domain for mediation of apoptosis is correlated with specific PIG3 gene transactivation and with transcriptional repression.
    Venot C; Maratrat M; Dureuil C; Conseiller E; Bracco L; Debussche L
    EMBO J; 1998 Aug; 17(16):4668-79. PubMed ID: 9707426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Why are there hotspot mutations in the TP53 gene in human cancers?
    Baugh EH; Ke H; Levine AJ; Bonneau RA; Chan CS
    Cell Death Differ; 2018 Jan; 25(1):154-160. PubMed ID: 29099487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential.
    Dumont P; Leu JI; Della Pietra AC; George DL; Murphy M
    Nat Genet; 2003 Mar; 33(3):357-65. PubMed ID: 12567188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of p53 oligomerization domain mutations isolated from Li-Fraumeni and Li-Fraumeni like family members.
    Lomax ME; Barnes DM; Hupp TR; Picksley SM; Camplejohn RS
    Oncogene; 1998 Aug; 17(5):643-9. PubMed ID: 9704930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.